H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Phasebio Pharmaceuticals (PHAS – Research Report) today and set a price target of $18.00. The company’s shares closed last Friday at $1.19.
Fein covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Vertex Pharmaceuticals, and Concert Pharma. According to TipRanks, Fein has an average return of -4.4% and a 41.48% success rate on recommended stocks.
Phasebio Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $13.00, a 992.44% upside from current levels. In a report released on August 12, Needham also maintained a Buy rating on the stock with a $8.00 price target.
See today’s best-performing stocks on TipRanks >>
PHAS market cap is currently $57.94M and has a P/E ratio of -0.56.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PhaseBio Pharmaceuticals, Inc. is engaged in the development and commercialization of biotherapeutics for the treatment of orphan diseases. It focuses on cardiopulmonary disorders. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
Read More on PHAS:
- Achieve Life Sciences (ACHV) Gets a Buy from H.C. Wainwright
- H.C. Wainwright Sticks to Its Buy Rating for Vor Biopharma (VOR)
- H.C. Wainwright Remains a Buy on Unity Biotechnology (UBX)
- Needham Keeps Their Buy Rating on Alteryx (AYX)
- Eliem Therapeutics Reports Second Quarter Financial and Business Highlights
